Figure 1
James Young, MD, conducted this interview, which focuses on the paradigm shift toward conducting large-scale cardiovascular end point trials for drugs that are not primarily developed for that purpose. View the video at https://youtu.be/aFtCfZyd54E.
Figure 2
Steven Nissen, MD, shares his story of revealing in 2007 that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. View the video at https://youtu.be/aFtCfZyd54E.